Welcome, Guest. Please login or register.
July 12, 2024, 03:40:50 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 204
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 38
Total: 38


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Could the HCV Drug Sofosbuvir Be Cardiotoxic?  (Read 6360 times)

0 Members and 1 Guest are viewing this topic.

Offline charly8

  • Member
  • Posts: 113
Could the HCV Drug Sofosbuvir Be Cardiotoxic?
« on: April 01, 2015, 08:49:10 am »
Could somebody comment on this?  There is a lot of medical mumbo jumbo.


"he ISMP also noted that sofosbuvir was approved under breakthrough rules and "was one of the first noncancer drugs approved without a controlled efficacy trial for its largest patient population.""

"We know a third of the population in the RE-LY trial[4] harbored a single nucleotide polymorphism (rs2244613) that affects CES-1. These patients had lower dabigatran trough concentrations and lower rates of bleeding. Polymorphisms have also been recognized for the P-GP system.

Genetics, therefore, plays a role in how sofosbuvir is metabolized, absorbed, and cleared. You can imagine a subset of patients who are taking a P-GP–inhibiting drug—such as amiodarone—who could also have genetically altered sofosbuvir handling. These patients might be exposed to very high levels of either the prodrug or its active metabolite."
1a, VL  1.05 Mil, ALT 47
Fibrosure F3 December 2014
Fibroscan F0-F1 March 2015
1995 INT & RYB -non-responder
2007 PEGIN & RYB 72 weeks tx - partial responder relapsed
1/23/15 Started Harvoni 12 weeks, EOT 4/17
2 week blood work -  <15 Und. (ALT 25)
4 week blood work - <15 Und. (ALT 29)
2/20/15 added RYB (4 weeks into 12 of tx)
8 week blood work - <15 Und. (ALT 23)
(EOT) 12 week blood work - <15 Und.
4wk POST tx VL - Und. (ALT16, AST 17)


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.